Get all your news in one place.
100's of premium titles.
One app.
Start reading
Medical Daily
Medical Daily
Health
Dorothy Brooks

BIZARRE: Lyme vaccine data at idweek show protection was measured only after four doses across two tick seasons - What They Never Told You

New details from the Phase 3 trial of the leading Lyme disease vaccine candidate, presented at the IDWeek infectious disease meeting in Washington, show that its efficacy of more than 70% was measured only after participants had received all four doses and entered a second tick season. One independent expert said that timing raises a practical question for families: how long they would wait before being protected.

The vaccine, PF-07307405 (LB6V, formerly VLA15), is being developed by Pfizer and Valneva and is not approved anywhere. The presentation added participant numbers and safety conclusions but did not change the core result: The trial narrowly missed its main statistical target.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.